Overview

Fasudil Eye Drop in Retinopathy Of Prematurity(ROP)

Status:
Unknown status
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
Eligible eyes are randomly assigned into two groups. Group A receive Fasudil eye drops (concentration 0.5 percent) twice daily. Group B, receive artificial tears drop with the same frequency. Retinal specialists who are expert in Retinopathy Of Prematurity field will perform fundus examination regularly. The examiners are blind. The progression of normal retinal vascularization and need to treatment will be documented and compared between the two study groups. The topical eye drops are used until the retinal vascularization are complete (45 week after LMP) or the patient needs to be treated.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Shahid Beheshti University of Medical Sciences
Treatments:
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine
Fasudil
Lubricant Eye Drops
Ophthalmic Solutions